Vor Biopharma Inc. (VOR)
Every FINRA and SEC series the site collects for Vor Biopharma Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.4M
Short interest
settlement 2026-08-14
9.8
Days to cover
+1.4% vs prior
61.0%
Short share of volume
2026-09-11
45,043
Fails to deliver
settlement 2026-08-14
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in VOR is 7,350,765 shares, up 61,649 shares over the last month. Over the last 48 readings it ranged from 226,362 shares (28 November 2025) to 22,024,363 shares (15 September 2025). At the reported average volume of 747K shares a day that is 9.8 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/vor" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 7,350,765 | +1.4% | 747,112 | 9.84 |
| 2026-07-31 | 7,251,707 | -0.5% | 871,822 | 8.32 |
| 2026-07-15 | 7,289,116 | -5.9% | 1,667,524 | 4.37 |
| 2026-06-30 | 7,743,558 | +30.1% | 2,057,942 | 3.76 |
| 2026-06-15 | 5,951,225 | +23.5% | 834,099 | 7.13 |
| 2026-05-29 | 4,818,351 | +4.9% | 804,527 | 5.99 |
| 2026-05-15 | 4,595,199 | -7.3% | 873,880 | 5.26 |
| 2026-04-30 | 4,957,640 | +5.3% | 964,563 | 5.14 |
| 2026-04-15 | 4,706,707 | -17.3% | 1,347,900 | 3.49 |
| 2026-03-31 | 5,687,983 | +66.5% | 1,387,708 | 4.10 |
| 2026-03-13 | 3,416,161 | +0.9% | 611,657 | 5.59 |
| 2026-02-27 | 3,386,872 | +6.6% | 562,470 | 6.02 |
| 2026-02-13 | 3,177,963 | +24.5% | 771,282 | 4.12 |
| 2026-01-30 | 2,552,873 | +16.7% | 956,129 | 2.67 |
| 2026-01-15 | 2,188,337 | -3.5% | 1,172,261 | 1.87 |
| 2025-12-31 | 2,266,700 | +16.6% | 1,438,624 | 1.58 |
| 2025-12-15 | 1,943,561 | +758.6% | 4,925,320 | 1.00 |
| 2025-11-28 | 226,362 | -23.2% | 706,033 | 1.00 |
| 2025-11-14 | 294,571 | -67.7% | 1,309,128 | 1.00 |
| 2025-10-31 | 911,582 | -26.3% | 386,833 | 2.36 |
| 2025-10-15 | 1,236,759 | -8.2% | 534,052 | 2.32 |
| 2025-09-30 | 1,347,089 | -93.9% | 450,344 | 2.99 |
| 2025-09-15 | 22,024,363 | +11.3% | 4,771,126 | 4.62 |
| 2025-08-29 | 19,783,600 | +7.4% | 3,899,656 | 5.07 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of VOR volume is 61.0%, up 5.6 points over the last five sessions. Over the last 52 readings it ranged from 27.2% (10 July 2026) to 77.0% (11 August 2026). The latest reading is in line with the 30-session average of 59.3%, on 371K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 226K | 371K | 61.0% | 0 |
| 2026-09-10 | 177K | 254K | 69.8% | 1,100 |
| 2026-09-09 | 159K | 266K | 59.7% | 0 |
| 2026-09-08 | 209K | 337K | 61.9% | 0 |
| 2026-09-04 | 105K | 165K | 63.8% | 0 |
| 2026-09-03 | 74K | 134K | 55.3% | 390 |
| 2026-09-02 | 167K | 262K | 63.8% | 0 |
| 2026-09-01 | 101K | 247K | 41.0% | 700 |
| 2026-08-31 | 97K | 141K | 68.9% | 0 |
| 2026-08-28 | 102K | 160K | 63.7% | 0 |
| 2026-08-27 | 129K | 257K | 50.0% | 0 |
| 2026-08-26 | 79K | 108K | 73.2% | 0 |
| 2026-08-25 | 130K | 452K | 28.9% | 0 |
| 2026-08-24 | 75K | 145K | 51.6% | 0 |
| 2026-08-21 | 91K | 164K | 55.5% | 0 |
| 2026-08-20 | 143K | 207K | 69.0% | 0 |
| 2026-08-19 | 142K | 307K | 46.1% | 81 |
| 2026-08-18 | 194K | 302K | 64.1% | 0 |
| 2026-08-17 | 108K | 196K | 54.8% | 1,215 |
| 2026-08-14 | 85K | 136K | 62.3% | 200 |
| 2026-08-13 | 191K | 358K | 53.4% | 0 |
| 2026-08-12 | 237K | 402K | 59.0% | 0 |
| 2026-08-11 | 180K | 234K | 77.0% | 1,711 |
| 2026-08-10 | 125K | 186K | 67.0% | 0 |
| 2026-08-07 | 203K | 323K | 62.7% | 750 |
| 2026-08-06 | 168K | 271K | 62.0% | 0 |
| 2026-08-05 | 134K | 225K | 59.3% | 0 |
| 2026-08-04 | 120K | 258K | 46.6% | 0 |
| 2026-08-03 | 161K | 274K | 58.7% | 0 |
| 2026-07-31 | 183K | 265K | 69.2% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in VOR is 45,043 shares, up 41,382 shares over the last settlement date. Over the last 52 readings it ranged from 7 shares (18 June 2026) to 362,289 shares (29 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 45,043 | $23.29 | $1.0M |
| 2026-08-13 | 3,661 | $22.34 | $82K |
| 2026-08-12 | 31 | $23.59 | $731 |
| 2026-08-06 | 955 | $22.27 | $21K |
| 2026-08-05 | 54,860 | $22.25 | $1.2M |
| 2026-08-04 | 25 | $21.41 | $535 |
| 2026-07-23 | 419 | $19.51 | $8K |
| 2026-07-22 | 4,705 | $20.05 | $94K |
| 2026-07-17 | 6,989 | $17.34 | $121K |
| 2026-07-10 | 35,172 | $19.75 | $695K |
| 2026-07-09 | 1,015 | $20.31 | $21K |
| 2026-07-08 | 104 | $20.10 | $2K |
| 2026-07-02 | 26,281 | $18.39 | $483K |
| 2026-06-30 | 166,073 | $18.60 | $3.1M |
| 2026-06-29 | 362,289 | $16.10 | $5.8M |
| 2026-06-26 | 675 | $14.93 | $10K |
| 2026-06-24 | 25,675 | $14.85 | $381K |
| 2026-06-23 | 52 | $14.94 | $777 |
| 2026-06-18 | 7 | $15.02 | $105 |
| 2026-06-16 | 1,207 | $14.07 | $17K |
| 2026-06-15 | 1,704 | $14.36 | $24K |
| 2026-06-12 | 1,811 | $14.09 | $26K |
| 2026-06-10 | 26,262 | $13.28 | $349K |
| 2026-06-08 | 561 | $13.16 | $7K |
| 2026-06-05 | 8,087 | $14.32 | $116K |
| 2026-06-03 | 2,387 | $13.66 | $33K |
| 2026-06-02 | 2,887 | $14.57 | $42K |
| 2026-04-29 | 554 | $14.38 | $8K |
| 2026-04-06 | 3,094 | $18.05 | $56K |
| 2026-04-02 | 3,600 | $17.39 | $63K |
Insider trades
SEC Form 4, newest first, 50 of 90 shown. JSONNo open-market insider trades were reported for VOR in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: RA CAPITAL MANAGEMENT, L.P. on 2026-08-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-24 | RA CAPITAL MANAGEMENT, L.P. | n/a | Option exercise | 2K | $3.74 | $6K | 2K |
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 165K | $15.77 | $2.6M | 2.4M |
| 2026-04-20 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 172K | $15.77 | $2.7M | 2.6M |
| 2026-04-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 458K | $16.28 | $7.5M | 2.7M |
| 2026-04-15 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 54K | $16.01 | $859K | 3.2M |
| 2026-04-14 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 154K | $15.97 | $2.5M | 3.3M |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 531K | $16.15 | $8.6M | 3.4M |
| 2026-04-10 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 828 | $15.75 | $13K | 3.9M |
| 2026-04-09 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 135K | $16.59 | $2.2M | 3.9M |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 131K | $16.91 | $2.2M | 4.1M |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 353K | $16.32 | $5.8M | 4.2M |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 7K | $18.50 | $125K | 4.6M |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 45K | $17.31 | $774K | 4.6M |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 538K | $16.51 | $8.9M | 4.6M |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 2K | $19.06 | $29K | 5.1M |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 258K | $18.23 | $4.7M | 5.1M |
| 2025-12-18 | RA CAPITAL MANAGEMENT, L.P. | n/a | Grant | 4.6M | $10.81 | $50.0M | 5.4M |
| 2025-12-05 | Mahatme Sandesh | CFO | Disposition | 694K | $0.00 | $0 | 0 |
| 2025-10-30 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 25K | $25.12 | $617K | 780K |
| 2025-10-29 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 252K | $25.22 | $6.3M | 804K |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 36K | $28.18 | $1.0M | 1.1M |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 88K | $27.10 | $2.4M | 1.1M |
| 2025-10-27 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 91K | $28.12 | $2.6M | 1.2M |
| 2025-10-24 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 53K | $28.01 | $1.5M | 1.3M |
| 2025-10-23 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 77K | $28.01 | $2.2M | 1.3M |
| 2025-10-21 | Reprogrammed Interchange LLC | n/a | Sell | 200 | $30.07 | $6K | 1.2M |
| 2025-10-21 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 25K | $28.11 | $704K | 1.4M |
| 2025-10-20 | Reprogrammed Interchange LLC | n/a | Sell | 12K | $30.05 | $349K | 1.2M |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 1K | $30.12 | $39K | 0 |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 7K | $30.12 | $197K | 1.4M |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 14K | $29.63 | $409K | 1K |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 70K | $29.63 | $2.1M | 1.4M |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 2K | $31.00 | $77K | 15K |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 13K | $31.00 | $393K | 1.5M |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 6K | $30.28 | $183K | 18K |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 31K | $30.28 | $931K | 1.5M |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 34K | $29.12 | $998K | 24K |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 175K | $29.12 | $5.1M | 1.5M |
| 2025-10-17 | Reprogrammed Interchange LLC | n/a | Sell | 1K | $31.00 | $32K | 1.2M |
| 2025-10-17 | Reprogrammed Interchange LLC | n/a | Sell | 25K | $30.22 | $746K | 1.2M |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 4 | $31.35 | $125 | 58K |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 20 | $31.35 | $627 | 1.7M |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 3K | $30.36 | $94K | 58K |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 16K | $30.36 | $480K | 1.7M |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 22K | $29.32 | $639K | 61K |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 111K | $29.32 | $3.3M | 1.7M |
| 2025-10-16 | Reprogrammed Interchange LLC | n/a | Sell | 2K | $30.45 | $62K | 1.2M |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 46 | $31.17 | $1K | 83K |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 234 | $31.17 | $7K | 1.8M |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | n/a | Sell | 8K | $30.55 | $256K | 83K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON24 holders above 5% have filed on VOR, 4 on Schedule 13D (active intent). The largest reported stake is Peter Kolchinsky at 19.9% of the class (12,937,855 shares), filed 2026-07-21 for an event on 2026-07-16.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 3 | Venrock Healthcare Capital Partners III, L.P.partnership | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Bong Y. Kohindividual | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Nimish Shahindividual | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | VHCP Management EG, LLCother entity | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | VHCP Management III, LLCother entity | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Venrock Healthcare Capital Partners EG, L.P.partnership | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | VHCP Co-Investment Holdings III, LLCother entity | 5.7M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLSP, L.L.C.other entity | 2.3M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences Public Fund, L.P.partnership | 2.3M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLSP, L.P.partnership | 2.3M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences XII, L.P.partnership | 265K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XII, L.L.C.other entity | 265K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XII, L.P.partnership | 265K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Frazier Life Sciences XI, L.P.partnership | 21K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XI, L.P.partnership | 21K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | FHMLS XI, L.L.C.other entity | 21K | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | Verve Capital Limitedcorporation | 3.4M | 6.3% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 6.5M | 12.0% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 1 | FMR LLCparent holding company | 6.5M | 12.0% | 2026-07-31 |
| 2026-08-06 | 13G | Abigail P. Johnsonindividual | 4.9M | 9.1% | 2026-06-30 |
| 2026-08-06 | 13G | FMR LLCparent holding company | 4.9M | 9.1% | 2026-06-30 |
| 2026-07-30 | 13G | BlackRock, Inc.parent holding company | 3.1M | 5.7% | 2026-06-30 |
| 2026-07-21 | 13D/Ano. 18 | Peter Kolchinskyparent holding company, individual | 12.9M | 19.9% | 2026-07-16 |
| 2026-07-21 | 13D/Ano. 18 | RA Capital Healthcare Fund, L.P.partnership | 12.9M | 19.9% | 2026-07-16 |
| 2026-07-21 | 13D/Ano. 18 | Rajeev Shahparent holding company, individual | 12.9M | 19.9% | 2026-07-16 |
| 2026-07-21 | 13D/Ano. 18 | RA Capital Management, L.P.investment adviser, partnership | 12.9M | 19.9% | 2026-07-16 |
13F holders
Tracked managers holding VOR at their latest 13F. JSON5 of the 30 tracked managers held VOR at their latest 13F, $13.1M in total at quarter-end prices. Millennium Management is the largest at $7.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 428K | $7.9M | 0.00% | +169K |
| Citadel Advisors | 2026-06-30 | 160K | $3.0M | 0.00% | +12K |
| D. E. Shaw & Co. | 2026-06-30 | 55K | $1.0M | 0.00% | +43K |
| Two Sigma Investments | 2026-06-30 | 37K | $681K | 0.00% | -133K |
| Renaissance Technologies | 2026-06-30 | 33K | $608K | 0.00% | -96K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$142.7M of operating cash flow.
- Cash
- $107.9M
- Equity
- -$200.2M
- Total assets
- $481.1M
- Shares outstanding
- 59,162,294
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | n/a | -$62.8M | n/a | -1.16 |
| Q1 2026 | 2026-03-31 | n/a | -$219.6M | n/a | -5.11 |
| Q4 2025derived | 2025-12-31 | n/a | $1.72B | n/a | n/a |
| Q3 2025 | 2025-09-30 | n/a | -$812.7M | n/a | -121.63 |
| Q2 2025 | 2025-06-30 | n/a | -$1.57B | n/a | -251.24 |
| Q1 2025 | 2025-03-31 | n/a | -$32.5M | n/a | -5.21 |
| Q4 2024derived | 2024-12-31 | n/a | -$30.7M | n/a | n/a |
| Q3 2024 | 2024-09-30 | n/a | -$27.6M | n/a | -8.05 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$696.0M | -$142.7M | $941K | n/a | $0 |
| FY 2024 | 2024-12-31 | n/a | -$116.9M | -$99.7M | $229K | n/a | $0 |
| FY 2023 | 2023-12-31 | n/a | -$117.9M | -$100.3M | $1.1M | n/a | $0 |
| FY 2022 | 2022-12-31 | n/a | -$92.1M | -$85.1M | $8.5M | n/a | $0 |
| FY 2021 | 2021-12-31 | n/a | -$68.9M | -$69.1M | $3.9M | n/a | $0 |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-06 from the cover page.
What this page is
Vor Biopharma Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Vor Biopharma Inc. (VOR), SEC CIK 1817229, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1817229Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of VOR is sold short?
What is VOR's daily short volume?
Does VOR have fails to deliver?
Are VOR insiders buying or selling?
Who owns more than 5% of VOR?
What did VOR report last quarter?
Which funds hold VOR?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.